Table of Contents
International Journal of Molecular Imaging
Volume 2012, Article ID 278306, 9 pages
Research Article

𝟏 πŸ– πŸ– R e -SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside

1Centre Régional de Lutte Contre le Cancer Eugène Marquis, INSERM UMR-S 991, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042 Rennes, France
2Ecole Nationale Supérieure de Chimie de Rennes, CNRS UMR 6226, Avenue du Général Leclerc, CS 50837, 35708 Rennes, France
3Université Européenne de Bretagne, 35000 Rennes, France

Received 12 October 2011; Revised 8 December 2011; Accepted 13 December 2011

Academic Editor: John Humm

Copyright © 2012 Nicolas Lepareur et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Hepatocellular carcinoma (HCC) is the 5th most common tumour worldwide and has a dark prognosis. For nonoperable cases, metabolic radiotherapy with Lipiodol labelled with β-emitters is a promising therapeutic option. The Comprehensive Cancer Centre Eugène Marquis and the National Graduate School of Chemistry of Rennes (ENSCR) have jointly developed a stable and efficient labelling of Lipiodol with rhenium-188 ( E 𝛽 m a x = 2 . 1  MeV) for the treatment of HCC. The major “milestones” of this development, from the first syntheses to the recent first injection in man, are described.